Patents by Inventor Eileen Sun CHIN
Eileen Sun CHIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220160871Abstract: Provided are methods involving the use of biomarkers, in relation to photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on tumor cell, for example, an IR700-antibody conjugate, and combination therapies, for example, that include photoimmunotherapy and an additional therapeutic agent, such as an immune modulating agent. In some aspects, the provided embodiments can be used to identify or select subjects for photoimmunotherapy and/or the combination therapy, or to assess the likelihood of response to photoimmunotherapy and/or to the additional therapeutic agents. Features of the methods and uses provide various advantages, such as improved efficacy. In some aspects, the provided embodiments can be used to provide personalized medicine and tailored therapy regimens for subjects.Type: ApplicationFiled: March 27, 2020Publication date: May 26, 2022Applicant: Rakuten Medical, Inc.Inventors: Miguel GARCIA-GUZMAN, Roger HEIM, Eileen Sun CHIN, Jerry FONG, Deepak YADAV, Nikolai SUSLOV, C. Daniel DE MAGALHAES FILHO, Chung-Wein LEE
-
Publication number: 20220105184Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: September 16, 2021Publication date: April 7, 2022Applicant: Rakuten Medical, Inc.Inventors: Merrill BIEL, Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Publication number: 20210401986Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: Rakuten Medical, Inc.Inventors: Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Publication number: 20210401985Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: Rakuten Medical, Inc.Inventors: Merrill BIEL, Lewis R. Makings, Roger Heim, Miguel Garcia-Guzman, Eileen Sun Chin, Deepak Yadav, Jerry Fong
-
Patent number: 11154620Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: GrantFiled: August 18, 2016Date of Patent: October 26, 2021Assignee: Rakuten Medical, Inc.Inventors: Miguel Garcia-Guzman, Eileen Sun Chin, Deepak Yadav, Jerry Fong
-
Publication number: 20190365897Abstract: Provided are conjugates, e.g., dual conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye in the dual conjugate. In some embodiments, the dual conjugate contains a targeting molecule and a therapeutic agent. In some embodiments, the phthalocyanine-dye in the conjugate, e.g., dual conjugate, can be activated by irradiation with near-infrared light. Also provided are therapeutic methods using the conjugates, e.g., dual conjugates, and compositions for treatment of a lesion associated with diseases and conditions, including tumors or cancers. Features of the conjugates, e.g., dual conjugates, compositions, combinations and methods, including the dose of the conjugate, provide various advantages, such as efficient delivery and targeting of the therapeutic agent to the site of the lesion.Type: ApplicationFiled: February 22, 2018Publication date: December 5, 2019Applicants: Rakuten Medical, Inc., Rakuten Medical, Inc.Inventors: Miguel GARCIA-GUZMAN, Lewis R. MAKINGS, Eileen Sun CHIN
-
Publication number: 20190015510Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.Type: ApplicationFiled: August 18, 2016Publication date: January 17, 2019Applicants: Aspyrian Therapeutics, Inc., Aspyrian Therapeutics, Inc.Inventors: Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG
-
Publication number: 20180250405Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.Type: ApplicationFiled: August 18, 2016Publication date: September 6, 2018Applicant: Aspyrian Therapeutics, Inc.Inventors: Merrill BIEL, Lewis R. MAKINGS, Roger HEIM, Miguel GARCIA-GUZMAN, Eileen Sun CHIN, Deepak YADAV, Jerry FONG